ICD Code A49.01

ICD code A49.01 is methicillin-susceptible Staphylococcus aureus (MSSA) infection at an unspecified site in the body.

1. Laboratory confirmation of Staphylococcus aureus infection that is methicillin susceptible

2. Clinical evidence of infection without a specified anatomical site

3. Presence of symptoms such as fever, chills, or localized signs of infection

4. Absence of documentation specifying the exact location of the infection

5. No evidence of methicillin resistance in the organism

6. Provider documentation indicating Staphylococcus aureus as the causative agent without further site specification

Relevant CPT codes that may be used to treat ICD code A49.01 include:

- 99201–99499 (Evaluation and Management services, depending on setting and complexity)

- 87040 (Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates)

- 87070 (Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates)

- 96365–96376 (Intravenous infusion, for therapy, prophylaxis, or diagnosis)

- 36415 (Collection of venous blood by venipuncture)

- 96372 (Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular)

- 96374 (Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug)

- 99291–99292 (Critical care services, if applicable)

- 10160 (Incision and drainage of abscess, if indicated)

- 11042–11047 (Debridement, if indicated)

- J3420 (Injection, vancomycin, if used)

- J0696 (Injection, ceftriaxone, if used)

- J3010 (Injection, fentanyl citrate, if used for pain management)

CPT code selection should be based on the specific clinical scenario and services rendered for ICD code A49.01.

Schedule a demo to see how MD Clarity’s RevFind software can automatically read your contracts and identify underpayments for CPT codes associated with ICD code A49.01. Discover how easy it is to ensure accurate reimbursement and maximize your revenue with RevFind.